Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot multiple sclerosis (MS) imaging study conducted with Massachusetts General Hospital, with preliminary PET imaging data showing encouraging signals in acute MS lesions, according to a company announcement. The novel imaging technique is designed to distinguish demyelinated nerve fibers that may still be viable from permanent nerve damage, potentially offering a more precise way to measure myelin loss and repair.
“These findings are directly relevant to Lucid-MS, the company’s investigational compound designed to inhibit demyelination by targeting the enzyme PAD2, which is implicated in myelin degradation,” reads a recent article. “A more precise imaging tool and a drug candidate designed to address the underlying cause of MS make for a compelling combination. Reaching the enrollment midpoint with promising early data suggests the science is holding up under real clinical conditions.”
The study’s significance lies in its potential to improve how clinicians assess treatments for MS, a chronic autoimmune disease affecting the central nervous system. Current imaging techniques often fail to differentiate between reversible myelin damage and permanent axonal loss, limiting their utility in monitoring disease progression and response to therapy. If validated, the new PET imaging method could provide a non-invasive biomarker for myelin repair, accelerating clinical trials for remyelinating therapies.
Quantum BioPharma is a biopharmaceutical company focused on developing treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is developing Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of MS. The company’s pipeline also includes unbuzzd, a product for alcohol misuse, for which it retains a 19.84% ownership stake in the OTC version’s company, Unbuzzd Wellness Inc., along with royalty payments starting at 7% of sales until $250 million, then dropping to 3% in perpetuity.
The favorable preliminary data from the imaging study could have broader implications for the MS research community, as it may enable more sensitive endpoint measurements in future trials, thereby reducing the time and cost required to demonstrate efficacy of new therapies. For Quantum BioPharma, a successful imaging biomarker would complement its drug development efforts, potentially accelerating the regulatory approval process for Lucid-MS.
Investors and researchers will be watching closely as the study progresses to its final stages. The company has not yet released specific data from the imaging results, but the encouraging signals suggest that the technique is capable of capturing meaningful changes in MS lesions. This development aligns with the growing emphasis on precision medicine in neurology, where treatments are tailored to the underlying pathology of individual patients.
For more information, visit the full article at https://nnw.fm/fsDHa and the company’s newsroom at https://ibn.fm/QNTM.
